Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00

Bicara Therapeutics (NASDAQ:BCAX) had its price objective lifted by HC Wainwright from $42.00 to $45.00 in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other brokerages also recently issued reports on BCAX. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective for the company. TD Cowen initiated coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating for the company. RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, Morgan Stanley began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics presently has an average rating of “Buy” and a consensus target price of $43.75.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $11.76 on Monday. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09. The firm’s 50-day moving average price is $16.65.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities analysts expect that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. purchased a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $177,169,000. FMR LLC bought a new stake in Bicara Therapeutics during the third quarter valued at about $57,913,000. Braidwell LP bought a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $42,219,000. Janus Henderson Group PLC bought a new position in Bicara Therapeutics in the 3rd quarter worth approximately $30,329,000. Finally, Baker BROS. Advisors LP purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.